Last $44.06 USD
Change Today 0.00 / 0.00%
Volume 0.0
CRTSF On Other Exchanges
Symbol
Exchange
Copenhagen
OTC US
OTC US
Frankfurt
As of 8:10 PM 12/16/14 All times are local (Market data is delayed by at least 15 minutes).

chr hansen holding a/s (CRTSF) Snapshot

Open
$44.06
Previous Close
$44.06
Day High
$44.06
Day Low
$44.06
52 Week High
04/24/14 - $45.42
52 Week Low
10/20/14 - $36.07
Market Cap
5.9B
Average Volume 10 Days
10.0
EPS TTM
--
Shares Outstanding
134.5M
EX-Date
11/28/14
P/E TM
--
Dividend
$3.83
Dividend Yield
1.40%
Current Stock Chart for CHR HANSEN HOLDING A/S (CRTSF)

Related News

No related news articles were found.

chr hansen holding a/s (CRTSF) Related Businessweek News

No Related Businessweek News Found

chr hansen holding a/s (CRTSF) Details

Chr. Hansen Holding A/S, a bioscience company, develops and sells natural ingredient solutions for the food, nutritional, pharmaceutical, and agricultural industries. The company’s Cultures and Enzymes division produces and sells cultures, enzymes, and probiotic products that determine the taste, flavor, color, texture, safety, preservation, nutritional value, and health benefits of various consumer products in the food and dairy industries. Its Health and Nutrition division provides probiotic cultures for the dietary supplement, over-the-counter pharmaceutical, infant formula, and animal feed and plant protection industries. The company’s Natural Colors division offers natural color solutions for the food industries, primarily including the beverage, confectionery, ice cream, dairy, fruit preparation, and prepared food segments. It has strategic alliance with FMC Corporation for development and commercialization of biological plant protection products. The company operates in Europe, the Middle East, Africa, North and South America, and the Asia Pacific. Chr. Hansen Holding A/S was founded in 1874 and is headquartered in Hørsholm, Denmark.

2,545 Employees
Last Reported Date: 10/23/14
Founded in 1874

chr hansen holding a/s (CRTSF) Top Compensated Officers

Chief Executive Officer, President and Member...
Total Annual Compensation: €890.0K
Chief Financial Officer and Member of Executi...
Total Annual Compensation: €600.0K
Executive Vice President of Cultures & Enzyme...
Total Annual Compensation: €620.0K
Compensation as of Fiscal Year 2014.

chr hansen holding a/s (CRTSF) Key Developments

Chr. Hansen Holding A/S - Shareholder/Analyst Call

Annual General Meeting

Chr. Hansen Holding A/S Proposes Amendment to its Articles of Association

Chr. Hansen Holding A/S announced the AGM to be held on November 27, 2014 to approve the amendment of the company's overall guidelines for incentive-based remuneration for Chr. Hansen Holding A/S' management. Pursuant to the revised overall guidelines, members of the Executive Board may, at the discretion of the Board of Directors, be invited to participate in a new Matching Shares Program. As a result of implementation of the new Matching Shares Program, the Board of Directors' powers to make new ordinary grants of share options under the existing Long-term Share Option Program will lapse. Adoption of the revised overall guidelines for incentive-based remuneration entails that Article 10.3 of the Articles of Association will be amended as follows: 10.3 - The Board of Directors has laid down overall guidelines for incentive-based remuneration for the Executive Board. These guidelines have been considered and approved at the company's Annual General Meeting held on 27 November 2014, cf. Section 139 of the Companies Act.

Chr. Hansen Holding A/S Reports Audited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended August 31, 2014; Provides Earnings Guidance for the Fiscal Year 2015

Chr. Hansen Holding A/S reported audited consolidated earnings results for the fourth quarter and full year ended August 31, 2014. For the year, the company reported revenue of EUR 756.2 million against EUR 738.4 million a year ago. Negative impacts from the currency developments. It leads the company to an organic growth of 8% in the middle of the 7% to 9% range. Operating profit (EBIT) was EUR 195.1 million against EUR 192.5 million a year ago. Profit before tax was EUR 181.3 million against EUR 176.7 million a year ago. Profit for the year attributable to shareholders was EUR 132.2 million against EUR 137.8 million a year ago. Diluted earnings per share were EUR 1.00 against EUR 1.04 a year ago. Cash flow from operating activities was EUR 176.4 million against EUR 190.3 million a year ago. Free cash flow was EUR 114.6 million against EUR 120.0 million a year ago. Investments in intangible assets were EUR 12.2 million against EUR 18.3 million a year ago. Investments in property, plant and equipment was EUR 50.6 million against EUR 52.7 million a year ago. Net interest-bearing debt was EUR 404 million. Result was negatively impacted by special items of about EUR 10 million. For the quarter, the company reported revenue of EUR 205 million against EUR 194 million a year ago. EBITDA before special items was EUR 75 million against EUR 72 million a year ago. EBIT before special items was EUR 62 million against EUR 60 million a year ago. EBIT was EUR 57 million against EUR 60 million a year ago. Profit before tax was EUR 53 million against EUR 56 million a year ago. Profit for the year was EUR 38 million against EUR 52 million a year ago. Diluted earnings per share were EUR 0.30 against EUR 0.39 a year ago. Cash flow from operating activities was EUR 94 million against EUR 92 million a year ago. Free cash flow was EUR 73 million against EUR 68 million a year ago. Capital expenditure was 10.9% against 12.4% a year ago. For the fiscal year 2015, the company would expect an effective tax rate around 26% for the group. Organic revenue growth is expected to be 79%. Free cash flow before acquisitions, divestments and special items is expected to be above EUR 130 million. The EBIT margin before special items is expected to be above 26.5%. Research & development expenditures incurred are expected to be 78% of revenue, due mainly to higher activity in strategic initiatives.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CRTSF:US $44.06 USD 0.00

CRTSF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Balchem Corp $67.01 USD +0.58
Corbion NV €13.60 EUR +0.085
Ebro Foods SA €13.70 EUR +0.04
Koninklijke Wessanen NV €5.29 EUR -0.046
Sensient Technologies Corp $61.39 USD +0.24
View Industry Companies
 

Industry Analysis

CRTSF

Industry Average

Valuation CRTSF Industry Range
Price/Earnings 33.6x
Price/Sales 5.6x
Price/Book 6.7x
Price/Cash Flow 34.2x
TEV/Sales 5.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CHR HANSEN HOLDING A/S, please visit www.chr-hansen.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.